G

Grand Pharmaceutical Group Ltd
HKEX:512

Watchlist Manager
Grand Pharmaceutical Group Ltd
HKEX:512
Watchlist
Price: 5.86 HKD -1.51%
Market Cap: 20.8B HKD
Financials Section:
Income Statement Balance Sheet Cash Flow Statement

Income Statement

0
Revenue
+0%
3Y
+35%
5Y
+77%
10Y
+273%
0
Operating Income
+0%
3Y
+2%
5Y
+66%
10Y
+601%
0
Net Income
+0%
3Y
+3%
5Y
+114%
10Y
+1 309%

Earnings Waterfall
Grand Pharmaceutical Group Ltd

Revenue
11.6B HKD
Cost of Revenue
-4.9B HKD
Gross Profit
6.7B HKD
Operating Expenses
-4.5B HKD
Operating Income
2.2B HKD
Other Expenses
248.9m HKD
Net Income
2.5B HKD

Income Statement
Grand Pharmaceutical Group Ltd

Rotate your device to view
Income Statement
Currency: HKD
Millions
Ones
Thousands
Millions
Billions
TTM
Quarterly
Annual
TTM
Dec-2004 Jun-2005 Dec-2005 Jun-2006 Dec-2006 Jun-2007 Dec-2007 Jun-2008 Dec-2008 Jun-2009 Dec-2009 Jun-2010 Dec-2010 Jun-2011 Dec-2011 Jun-2012 Dec-2012 Jun-2013 Dec-2013 Jun-2014 Dec-2014 Jun-2015 Dec-2015 Jun-2016 Dec-2016 Jun-2017 Dec-2017 Jun-2018 Dec-2018 Jun-2019 Dec-2019 Jun-2020 Dec-2020 Jun-2021 Dec-2021 Jun-2022 Dec-2022 Jun-2023 Dec-2023 Jun-2024 Dec-2024
Revenue
Revenue
63
N/A
62
-2%
46
-25%
45
-3%
42
-6%
44
+3%
49
+12%
60
+22%
270
+349%
514
+91%
545
+6%
677
+24%
1 055
+56%
1 486
+41%
1 648
+11%
1 866
+13%
2 059
+10%
2 328
+13%
2 658
+14%
2 958
+11%
3 122
+6%
3 071
-2%
3 246
+6%
3 450
+6%
3 696
+7%
4 190
+13%
4 771
+14%
5 732
+20%
5 958
+4%
6 309
+6%
6 591
+4%
6 259
-5%
6 353
+1%
7 664
+21%
8 598
+12%
9 244
+8%
9 562
+3%
10 339
+8%
10 530
+2%
10 587
+1%
11 645
+10%
Gross Profit
Cost of Revenue
(43)
(44)
(26)
(25)
(23)
(24)
(26)
(32)
(160)
(292)
(295)
(391)
(680)
(999)
(1 133)
(1 291)
(1 414)
(1 596)
(1 772)
(1 915)
(1 929)
(1 842)
(1 895)
(1 954)
(1 964)
(2 065)
(2 291)
(2 539)
(2 797)
(2 743)
(2 549)
(2 450)
(2 318)
(2 776)
(3 351)
(3 630)
(3 611)
(3 779)
(4 006)
(4 340)
(4 907)
Gross Profit
21
N/A
18
-12%
20
+12%
20
-1%
19
-5%
20
+4%
23
+15%
28
+23%
110
+292%
223
+103%
250
+12%
286
+14%
375
+31%
487
+30%
515
+6%
575
+12%
645
+12%
732
+14%
887
+21%
1 043
+18%
1 194
+14%
1 230
+3%
1 350
+10%
1 496
+11%
1 732
+16%
2 125
+23%
2 479
+17%
3 193
+29%
3 162
-1%
3 567
+13%
4 041
+13%
3 809
-6%
4 035
+6%
4 887
+21%
5 247
+7%
5 614
+7%
5 951
+6%
6 560
+10%
6 524
-1%
6 247
-4%
6 738
+8%
Operating Income
Operating Expenses
(166)
(160)
(122)
(107)
(26)
(35)
(69)
(75)
(111)
(181)
(197)
(219)
(190)
(291)
(390)
(462)
(488)
(556)
(677)
(781)
(877)
(875)
(996)
(1 038)
(1 275)
(1 496)
(1 787)
(2 294)
(2 200)
(2 313)
(2 701)
(2 307)
(2 252)
(2 789)
(3 066)
(3 016)
(3 205)
(3 914)
(3 665)
(3 512)
(4 519)
Selling, General & Administrative
(66)
(58)
(63)
(50)
(39)
(46)
(75)
(83)
(117)
(185)
(204)
(231)
(330)
(437)
(468)
(526)
(577)
(646)
(772)
(884)
(981)
(971)
(1 041)
(1 170)
(1 302)
(1 591)
(1 847)
(2 415)
(2 311)
(2 537)
(2 910)
(2 586)
(2 563)
(3 124)
(3 308)
(3 388)
(3 374)
(3 783)
(3 861)
(3 745)
(4 696)
Depreciation & Amortization
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
(0)
(2)
0
0
0
(12)
0
(12)
0
(13)
0
(16)
0
(8)
0
0
0
0
0
0
0
0
0
0
Other Operating Expenses
(100)
(101)
(59)
(57)
13
11
5
8
7
4
7
12
141
146
78
65
90
90
97
104
103
96
57
132
39
95
73
122
126
225
217
279
311
335
242
371
168
(131)
195
234
177
Operating Income
(145)
N/A
(142)
+3%
(102)
+28%
(87)
+15%
(7)
+92%
(15)
-124%
(47)
-207%
(47)
0%
(1)
+99%
42
N/A
53
+27%
67
+25%
185
+178%
196
+6%
125
-36%
114
-9%
157
+38%
176
+12%
210
+19%
262
+25%
317
+21%
354
+12%
354
+0%
458
+29%
457
0%
629
+38%
693
+10%
899
+30%
961
+7%
1 254
+30%
1 340
+7%
1 503
+12%
1 783
+19%
2 098
+18%
2 182
+4%
2 598
+19%
2 746
+6%
2 645
-4%
2 859
+8%
2 735
-4%
2 220
-19%
Pre-Tax Income
Interest Income Expense
(11)
(9)
(7)
(8)
(5)
(5)
(9)
(11)
(14)
3
(4)
(27)
(49)
(40)
(26)
(22)
(42)
(50)
(77)
(98)
(114)
(128)
(134)
(189)
(167)
(179)
(157)
(197)
(106)
(100)
(12)
45
282
512
602
(305)
(195)
378
(99)
154
628
Non-Reccuring Items
0
0
0
0
0
0
0
0
(8)
(8)
0
18
22
4
0
0
0
0
0
0
0
0
20
0
24
0
23
0
29
0
28
0
9
0
2
0
(34)
(96)
(415)
(39)
5
Total Other Income
(0)
0
0
0
0
0
0
0
0
(9)
0
0
0
0
0
0
0
0
0
0
0
0
0
(0)
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
Pre-Tax Income
(157)
N/A
(151)
+4%
(109)
+28%
(95)
+13%
(12)
+87%
(21)
-68%
(56)
-173%
(58)
-4%
(23)
+61%
28
N/A
49
+72%
58
+18%
158
+174%
160
+1%
99
-38%
92
-7%
116
+26%
126
+9%
132
+5%
164
+24%
203
+24%
227
+12%
241
+6%
269
+12%
314
+17%
450
+43%
559
+24%
702
+26%
884
+26%
1 154
+31%
1 356
+18%
1 548
+14%
2 074
+34%
2 611
+26%
2 786
+7%
2 293
-18%
2 517
+10%
2 927
+16%
2 344
-20%
2 850
+22%
2 852
+0%
Net Income
Tax Provision
0
0
0
0
0
0
2
2
0
(3)
(7)
(10)
(4)
(3)
(13)
(10)
(11)
(18)
(27)
(35)
(27)
(32)
(40)
(42)
(45)
(63)
(73)
(102)
(147)
(200)
(230)
(272)
(292)
(331)
(381)
(394)
(419)
(470)
(449)
(424)
(386)
Income from Continuing Operations
(157)
(151)
(109)
(95)
(12)
(20)
(54)
(56)
(23)
25
42
48
154
157
87
82
105
109
105
129
176
195
200
227
269
387
486
600
736
954
1 125
1 276
1 781
2 280
2 405
1 899
2 098
2 457
1 895
2 426
2 466
Income to Minority Interest
19
18
12
11
1
2
2
1
(4)
(11)
(14)
(23)
(56)
(54)
(32)
(32)
(37)
(27)
(6)
(3)
(1)
(1)
(20)
(14)
(0)
(23)
(25)
(29)
(24)
(9)
25
47
11
(3)
(2)
12
(19)
(59)
(15)
(18)
2
Net Income (Common)
(138)
N/A
(132)
+4%
(97)
+27%
(84)
+13%
(11)
+87%
(19)
-76%
(52)
-178%
(53)
-2%
(24)
+54%
14
N/A
28
+103%
25
-11%
98
+289%
103
+5%
54
-47%
50
-8%
67
+35%
82
+22%
100
+21%
126
+26%
175
+39%
194
+11%
181
-7%
213
+18%
269
+27%
364
+35%
461
+27%
570
+24%
713
+25%
944
+32%
1 151
+22%
1 323
+15%
1 793
+36%
2 277
+27%
2 403
+6%
1 910
-20%
2 079
+9%
2 398
+15%
1 880
-22%
2 409
+28%
2 468
+2%
EPS (Diluted)
-0.68
N/A
-0.16
+76%
-0.09
+44%
-0.08
+11%
-0.01
+88%
-0.01
N/A
-0.04
-300%
-0.05
-25%
-0.03
+40%
0.01
N/A
0.02
+100%
0.01
-50%
0.06
+500%
0.06
N/A
0.03
-50%
0.03
N/A
0.03
N/A
0.04
+33%
0.05
+25%
0.06
+20%
0.09
+50%
0.1
+11%
0.09
-10%
0.1
+11%
0.12
+20%
0.16
+33%
0.19
+19%
0.23
+21%
0.27
+17%
0.31
+15%
0.34
+10%
0.38
+12%
0.52
+37%
0.64
+23%
0.68
+6%
0.54
-21%
0.59
+9%
0.68
+15%
0.54
-21%
0.69
+28%
0.7
+1%

See Also

Summary
Intrinsic value, competitors valuation, and company profile.
DCF Valuation
Stock valuation using Discount Cash Flow valuation method.
Relative Valuation
Stock valuation using valuation multiples.
Wall Street Estimates
Price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
Stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
ALPHA SPREAD
Follow us
Join more than 250,400+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2025 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.